Tag: Ozempic
-
NAION Eye Side Effect for Ozempic and Mounjaro: Drug Injury Lawsuits Update January 2026
Federal Court MDL: IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Posted by Tom Lamb at Drug Injury Watch) In December 2025, the U.S. Judicial Panel on Multidistrict Litigation…
-
Wegovy and Ozempic Patients Get Compensation for NAION Vision Loss In Europe
Because Semaglutide is Linked to NAION, Wegovy and Ozempic Drug Injury Cases Have Been Filed In the US (Posted by Tom Lamb at Drug Injury Watch) For more than a year now, we have been looking into…
-
Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness
Semaglutide is the Active Ingredient in These GLP-1 Drugs Used for Diabetes or Weight Loss (Posted by Tom Lamb at Drug Injury Watch) Over the past year, we have written several articles that reference medical reports concerning…
-
More Evidence For Increased Risk of NAION With Ozempic or Mounjaro in Diabetes Patients
NAION is Likely Associated With Other Semaglutide or Tirzepatide GLP-1RA Drugs Used for Weight Loss (Posted by Tom Lamb at Drug Injury Watch) A new medical article published August 11, 2025, online by JAMA Network…
-
Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs
Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects (Posted by Tom Lamb at Drug Injury Watch) The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION)…
-
Ozempic Vision Loss Lawsuits Have Been Filed by Patients Against Novo Nordisk
We List Some of the Legal Liability Allegations Regarding Drug Company Actions and Failures (Posted by Tom Lamb at Drug Injury Watch) During the past several weeks, Ozempic vision loss lawsuits have been filed by…
-
March 2025 Medical Article About Blindness or Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
Discusses Timing for Increased Risk of Semaglutide-related Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Side Effect (Posted by Tom Lamb at Drug Injury Watch) On March 27, 2025, the JAMA Ophthalmology medical journal published a report…
-
Novo Nordisk Semaglutide Drug Ozempic Linked to Vision Loss, Doubling the Risk: December 2024 Update
European Drug Regulators Are Investigating Semaglutide-Related NAION Cases Presented in Two Danish Studies (Posted by Tom Lamb at Drug Injury Watch) According to this December 18, 2024, Reuters news report, "Novo Nordisk's Ozempic faces EU…